CINCINNATI, July 12 /PRNewswire/ — Ethicon
Endo-Surgery, Inc. (EES), a Johnson & Johnson company, today
announced it has completed the divestiture of its Breast Care
business to Devicor Medical Products, Inc., a portfolio company of
GTCR. Financial terms of the transaction are not being
disclosed.
Under the terms of the transaction, Devicor has acquired the
entire EES Breast Care product portfolio, including the
MAMMOTOME® Breast Biopsy System and tissue markers
(MammoMARK®, MicroMARK®, and
CoreMARK®) used for breast disease diagnostic
sampling and management. Additionally, EES has transferred
marketing and distribution rights for Neoprobe®
Gamma Detection Systems to Devicor. Approximately 300
employees supporting the business will transfer to Devicor, subject
to local laws.
“Associates in the Breast Care business have made it what it is
today: the global leader in vacuum assisted breast biopsy devices,”
said Karen Licitra, Company Group
Chairman, and Worldwide Franchise Chairman, Ethicon Endo-Surgery.
“The MAMMOTOME® brand is recognized worldwide, and we
believe Devicor provides a promising fit to help the Breast Care
business achieve its full potential.”
About Ethicon Endo-Surgery, Inc.
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company,
develops and markets advanced medical devices for minimally
invasive and open surgical procedures, focusing on
procedure-enabling devices for the interventional diagnosis and
treatment of conditions in general and bariatric surgery, as well
as gastrointestinal health, gynecology and surgical oncology. More
information can be found at
